Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06312813 · ClinicalTrials.gov registry record · Phase 2
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
A Phase 2 study of Rosacea, sponsored by Wright State University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06312813: Recruiting Phase 2 study of Rosacea, sponsored by Wright State University.
NCT06312813 is a Phase 2 study of Rosacea that is actively recruiting participants, run by Wright State University. The registered enrollment target is 48 participants, below the 241-participant average among 23 other Rosacea trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06312813, a Phase 2 study of Rosacea, is actively recruiting participants, sponsored by Wright State University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.
Primary Outcome
Erythema change from baseline with 4% imipramine application in response to a low level of UVB are measured by using a mexameter device and thermal photography.
Conditions Studied
Interventions
- DRUG Amitriptyline
- DRUG Imipramine
- DRUG Vehicle
Study Locations (1)
Ohio
- Wright State Physicians - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 2 |
What NCT06312813 shows while recruiting
NCT06312813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 241-participant average among 23 other Rosacea trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 3 interventions - of which Amitriptyline is the first listed.
NCT06312813 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06312813 about?
NCT06312813 is a clinical study titled "Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea". Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with r...
What is the current status of trial NCT06312813?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-02-27. Estimated completion is 2028-12-01.
What conditions does trial NCT06312813 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT06312813?
The interventions under investigation include: Amitriptyline (DRUG), Imipramine (DRUG), Vehicle (DRUG).
Who is sponsoring clinical trial NCT06312813?
This trial is sponsored by Wright State University, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06312813 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06312813's enrollment target sits among peer trials
48 18th of 23 higher than 6 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rosacea and Ivermectin
COMPLETED · Phase 2
-
AGN-199201 for the Treatment of Erythema With Rosacea
COMPLETED · Phase 2
-
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 2
-
A Study of DER 45-EV Gel to Treat Rosacea
COMPLETED · Phase 2
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI